Background and Purpose-Experimental studies provide evidence of an association between ischemic stroke and increased oxidative stress, but data in humans are still limited and controversial. The purpose of this study was to investigate the time course of plasma antioxidant changes in ischemic stroke patients. Methods-Plasma antioxidants, including water-soluble (vitamin C and uric acid) and lipid-soluble (vitamins A and E) compounds as well as antioxidant enzyme activities in plasma (superoxide dismutase [SOD] and glutathione peroxidase) and erythrocytes (SOD), were measured by high-performance liquid chromatography (antioxidant vitamins) and by spectrophotometry (antioxidant enzymes) in 38 subjects (25 men and 13 women aged 77.2Ϯ7.9 years) with acute ischemic stroke of recent onset (Ͻ24 hours) on admission, after 6 and 24 hours, and on days 3, 5, and 7. Antioxidant levels in patients on admission were compared with those of age-and sex-matched controls. Results-Mean antioxidant levels and activities in patients on admission were lower than those of controls and showed a gradual increase over time. Patients with the worst early outcome (death or functional decline) had higher vitamin A and uric acid plasma levels and lower vitamin C levels and erythrocyte SOD activity than those who remained functionally stable. Conclusions-These results suggest that the majority of antioxidants are reduced immediately after an acute ischemic stroke, possibly as a consequence of increased oxidative stress. A specific antioxidant profile is associated with a poor early outcome. (Stroke. 2000;31:2295-2300.)

These results suggest that an appropriate level of vitamin E and a low level of LDL oxidation might be important for reaching advanced age without developing atherosclerosis.

No abstract

lAGS 5. De Vos D, Slee PHTJ, Briggs RJ. Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 1992;3 1:76. 6. De Vos D, Slee PHTJ, Briggs RJ. Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels. Cancer Chernother Pharmacol 1998;42:512-514. 7. Winograd CH, Gerety MB, Chung M et al. Screening for frailty: Criteria and predictors of outcomes.